Innovative Cell Therapy Indapta specializes in allogeneic g-NK cells with potent ADCC activity, making their therapies highly promising for collaborations with pharmaceutical companies focusing on antibody-based treatments and immune cell engager molecules.
Strong Funding Momentum Recent funding rounds including a $60M Series A and multiple grants demonstrate robust investor confidence, positioning Indapta for accelerated clinical development and potential market entry of their innovative therapies.
Strategic Partnerships Collaborations with Sanofi Pasteur on multiple myeloma suggest opportunities to expand clinical development, joint ventures, and licensing deals within the oncology and immunotherapy markets.
Regulatory Milestones Receiving FDA Fast Track designation for IDP-023 highlights the company's potential to expedite regulatory approval processes, which can accelerate sales cycles and market access for their lead therapies.
Market Focus Focusing on cancers like non-Hodgkin's lymphoma and multiple myeloma offers clear targeting opportunities for biotech and pharmaceutical partners seeking innovative treatments for hematological malignancies with unmet needs.
$1M
$1M$10M
$1M$10M
$250M$500M
$1M$10M
$10M$25MIndapta Therapeutics uses 8 technology products and services including MySQL, oEmbed, Floating UI, and more. Explore Indapta Therapeutics's tech stack below.
| Indapta Therapeutics Email Formats | Percentage |
| FLast@indapta.com | 46% |
| First@indapta.com | 4% |
| FLast@indapta.com | 46% |
| First@indapta.com | 4% |
Biotechnology ResearchTexas, United States11-50 Employees
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
Company Overview
Funding & FinancialsIndapta Therapeutics's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsIndapta Therapeutics's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com